NCT05874141 is a NA clinical trial of HBA1C in Type 2 Diabetes, sponsored by New Valley University.

Who is sponsoring NCT05874141?

NCT05874141 is sponsored by New Valley University.

What drugs are being tested in NCT05874141?

Interventions in NCT05874141: HBA1C, Lipid profile, including total, LDL, and HDL cholesterol and Triglycerides, Urine analysis and urinary albumin-to-creatinine ratio, Serum creatinine and estimated glomerular filtration rate, Complete blood count, Thyroid-stimulating hormone, Serum iron, TIBC, Transferrin saturation and serum ferritin if needed, Electrocardiography (ECG), Transthoracic echocardiography, Neck ultrasonography if needed and abdominopelvic ultrasound, Arterial duplex ultrasound of both lower limbs, Random blood glucose, AST, ALT, albumin.

What condition does NCT05874141 study?

NCT05874141 studies Type 2 Diabetes.

Is NCT05874141 still recruiting?

NCT05874141 is currently recruiting now. Last updated 14 August 2025.

Last reviewed 2025-08-14 · How we verify

NCT05874141

Name: Drug Landscape Pharmaceutical Database
Creator: Drug Landscape
Published: 2026-01-01
License: https://creativecommons.org/licenses/by/4.0/

Comorbidities in Type 2 Diabetes Mellitus

Recruiting now NA Last updated 14 August 2025

What this trial tests

NA trial testing HBA1C in Type 2 Diabetes in 288 participants. Currently enrolling.

Timeline

15 November 2023

Primary endpoint
30 December 2025

30 August 2026

Quick facts

Lead sponsor	New Valley University
Phase	NA
Status	Recruiting now
Study type	INTERVENTIONAL
Allocation	na
Design	single group
Masking	none
Primary purpose	screening
Enrollment	288
Start date	15 November 2023
Primary completion	30 December 2025
Estimated completion	30 August 2026
Sites	1 location across Egypt

Drugs / interventions tested

HBA1C
Lipid profile, including total, LDL, and HDL cholesterol and Triglycerides
Urine analysis and urinary albumin-to-creatinine ratio
Serum creatinine and estimated glomerular filtration rate
Complete blood count
Thyroid-stimulating hormone
Serum iron, TIBC, Transferrin saturation and serum ferritin if needed
Electrocardiography (ECG)
Transthoracic echocardiography, Neck ultrasonography if needed and abdominopelvic ultrasound
Arterial duplex ultrasound of both lower limbs
Random blood glucose
AST, ALT, albumin

Conditions studied

Type 2 Diabetes — all drugs for Type 2 Diabetes →

Sponsor

New Valley University

Who can join

Adults 18 to 90, any sex, with Type 2 Diabetes. Patients with the condition only — healthy volunteers not accepted.

Sponsor's own description

Type 2 diabetes mellitus (DM) has adopted a top priority as it is a disease with an increasing prevalence. The number of people living with DM has increased more than fourfold over the past 40 years to more than 460 million people today

Publications & conference data

No peer-reviewed publications indexed yet for this trial.

Verify or expand the search:

Other recruiting trials for Type 2 Diabetes

Currently open trials in the same condition.

NCT07053319 — SGLT2i, Pioglitazone, and Ketone Production in T2D · Phase 1 · recruiting
NCT07272837 — Impact of Semaglutide (Ozempic/Wegovy®) on Heart and Muscle Mass · recruiting
NCT07463859 — Effects of Periodontal Treatment Associated With Antimicrobial Photodynamic Therapy on Halitosis in Patients With Diabet · NA · recruiting
NCT07254689 — The Food for Health Study · NA · recruiting
NCT07558863 — Effect of GLP-1RA on Cardiac Autonomic Neuropathy in Type 2 Diabetes · Phase 4 · recruiting

Other New Valley University trials

Trials by the same sponsor.

NCT06067399 — Relationship Between Red Cell Distribution Width (RDW) and HbA1C in Patients With Type 2 Diabetes Mellitus After Glycemi · recruiting
NCT06387667 — Characterizing Diversity and Antifungal Resistance in Immunocompromised ICU Patients With Respiratory Tract Infections · NA · not yet recruiting
NCT07142239 — Hematological Markers MPV, PLR, and NLR in Primary Versus Secondary Antiphospholipid Syndrome · not yet recruiting
NCT07171541 — Correlation Between OCT and Mf-ERG Findings With BCVA in Patients With Macular Dystrophy · not yet recruiting
NCT06490731 — Effects of Dexmedetomidine Versus Ketamine on Inflammatory Response and Hemodynamic in Patients · Phase 1, PHASE2 · recruiting

Verify against primary sources

ClinicalTrials.gov — authoritative US registry record
WHO ICTRP — international registry index
EU Clinical Trials Register
Sponsor press releases (Google)

Data sources for this page

Trial protocol + status: ClinicalTrials.gov NCT05874141 (US National Library of Medicine, public domain)
Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
Sponsor: as reported to ClinicalTrials.gov by New Valley University
Last refreshed: 14 August 2025

Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT05874141.

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing